Sales of new Alzheimer's drug fall short of expectations | The Hill: Healthcare Policy

Biogen’s sales for its new Alzheimer’s drug fell short of Wall Street expectations, with the drugmaker reporting on Wednesday that it brought in millions less than anticipated from Aduhelm in the third quarter.The first Alzheimer’s drug approved by...